Trials / Completed
CompletedNCT06906848
Evaluate the Effects of Citicoline on Cognitive Performance in Healthy Adults
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Effects of Cognizin ® Citicoline on Cognitive Performance in Generally Healthy Adults
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Kirin Holdings Company, Limited · Industry
- Sex
- All
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
Cognizin is a patented form of citicoline, a natural compound of the brain tissue. It is believed that Cognizin can support brain function by boosting brain energy and protecting brain cells. Research suggests that Cognizin can improve different aspects of brain function and affects cognitive performance in healthy adults.
Detailed description
This study is a prospective, randomized, placebo-controlled, double-blind trial designed to assess the effects of Cognizin on cognitive performance in healthy young adults. Participants will be randomized in a 1:1 ratio to either the test product (TP) or placebo (PL). During the study, participants cognitive performance will be assessed using the Psychomotor Vigilance Test (PVT) at baseline and after 12 weeks. Safety assessments will be conducted throughout the study. Note: The Unique Protocol ID K05-24-01-T0060 was unintentionally combined with another Unique Protocol ID, Bio-2104. As a result, the first protocol record for K05-24-01-T0060 was released in September 2024, prior to participant recruitment and randomization. The study start date was November 2024. This explanation has been added per PRS instructions to ensure compliance and maintain data integrity in alignment with the protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Placebo | Oral |
| DIETARY_SUPPLEMENT | Cognizin® | Oral |
Timeline
- Start date
- 2024-11-20
- Primary completion
- 2025-05-31
- Completion
- 2025-06-20
- First posted
- 2025-04-02
- Last updated
- 2025-07-09
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06906848. Inclusion in this directory is not an endorsement.